source
- STAT invites reader letters on primary care value, obesity as disease and broader health-care debatesSTAT’s First Opinion platform encourages readers to submit letters responding to its essays, fostering open, good‑faith discussion about health‑care topics. Recent letters, echoing comments from t…
- FDA approves Lipfendra, first oral PCSK9 inhibitor, to lower LDL cholesterol in adultsThe U.S. Food and Drug Administration has approved Lipfendra (enlicitide), the first oral inhibitor of the PCSK9 protein, for use as an adjunct to diet and exercise in adults with high cholesterol,…